BACKGROUND: Progerin, an aberrant protein that accumulates with age, causes the rare genetic disease Hutchinson-Gilford progeria syndrome (HGPS). Patients who have HGPS exhibit ubiquitous progerin expression, accelerated aging and atherosclerosis, and die in their early teens, mainly of myocardial infarction or stroke. The mechanisms underlying progerin-induced atherosclerosis remain unexplored, in part, because of the lack of appropriate animal models.
C ardiovascular disease (CVD) is the leading cause of death worldwide, despite major recent progress in its prevention, diagnosis, and treatment. 1, 2 Atherosclerosis, defined as the narrowing of the arterial lumen because of atheroma plaque buildup, underlies most manifestations of CVD and can lead to myocardial infarction or stroke.
Accelerated atherosclerosis is a predominant feature of the rare genetic disorder Hutchinson-Gilford progeria syndrome (HGPS). Classical HGPS is caused by a point mutation (c.1824C>T; p.G608G) in the LMNA gene resulting in ubiquitous expression of progerin, a mutant form of the nuclear envelope protein lamin A. 3, 4 Children with HGPS typically appear normal at birth, but within the first 2 years of life start to display the first signs of the disease, such as growth impairment and skin abnormalities. As childhood progresses, patients develop other symptoms, including alopecia, loss of body fat, joint stiffness, and osteoporosis, resembling many features of physiological aging. 5, 6 The most clinically relevant feature of HGPS is generalized atheroscle-rosis that leads to premature death from myocardial infarction or stroke at an average age of 14.6 years. 5, 7 Atherosclerosis in HGPS is accompanied by pathological changes in the aortic wall involving severe vascular smooth muscle cell (VSMC) depletion in the media, extracellular matrix deposition, calcification, and adventitial thickening. [8] [9] [10] Atherosclerotic disease in HGPS is particularly intriguing because patients lack the classical CVD risk factors, such as increased low-density lipoprotein (LDL) and C-reactive protein levels in serum. 11 HGPS therefore offers a unique opportunity to study CVD in isolation from typical risk factors. Because progerin also accumulates during normal aging, 10, 12, 13 studies of HGPS may enhance our knowledge about physiological aging and CVD. 14 As of October 1, 2017, there were 111 identified children living with HGPS worldwide, all of them carrying a progerin-producing mutation in the LMNA gene. 15 This extremely low number presents major difficulties for research into disease mechanisms and for clinical trials testing new therapeutic strategies. Several mouse models of HGPS have been generated, including Lmna HG , BAC G608G, Lmna G609G , and Zmpste24 -/-. [16] [17] [18] [19] [20] [21] [22] Although these mice recapitulate many aspects of the disease, none have been reported to develop atherosclerosis, the life-threatening symptom of HGPS. Thus, the aim of this study was to generate a mouse model exhibiting progerin-induced atherosclerosis acceleration and to study the relative contribution to progerindriven atherosclerosis of macrophages and VSMCs, the key players in atherogenesis.
METHODS
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure (available at the authors' laboratories).
Study Approval
All experimental and other scientific procedures with animals conformed to EU Directive 2010/63EU and Recommendation 2007/526/EC, enforced in Spanish law under Real Decreto 53/2013. Animal protocols were approved by the local ethics committees and the Animal Protection Area of the Comunidad Autónoma de Madrid (PROEX76/14, PROEX78/14, PROEX167/16). Blood for LDL isolation was obtained from healthy volunteers after informed consent in accordance with local ethics committee guidelines (Comité de Ética de la Investigación del Instituto de Salud Carlos III: CEI PI 12_2016-v2).
Mice
All mice used in this study were males on the C57BL/6J genetic background carrying the following genetic manipulations: Apoe -/-(The Jackson Laboratory, stock no: 002052),
Clinical Perspective
What Is New? • We have generated the first mouse model of progerin-induced acceleration of atherosclerosis, a major medical problem in patients with Hutchinson-Gilford progeria syndrome. • We provide the first direct evidence that progerin expression restricted to vascular smooth muscle cells (VSMCs), but not to macrophages, is sufficient to induce premature atherosclerosis and death. • We demonstrate that progerin-induced loss of VSMCs causes atherosclerotic plaque destabilization that may lead to myocardial infarction. • We show that ubiquitous and VSMC-specific progerin expression increases low-density lipoprotein retention in the aortic media, likely accelerating atherosclerosis.
What Are the Clinical Implications?
• Apoe -/-Lmna G609G/G609G mice ubiquitously expressing progerin constitute the first preclinical animal model for the study of accelerated atherosclerosis and premature aging. • Apoe -/-Lmna LCS/LCS SM22αCre mice with VSMCspecific progerin expression constitute the first preclinical animal model for the study of accelerated atherosclerosis isolated from other disease symptoms. • Because atherosclerosis is the main disease symptom leading to death in patients with Hutchinson-Gilford progeria syndrome, our studies point to VSMCs as a potential target for future therapies for this devastating disease.
Longevity Studies
Starting at 4 weeks of age, animals were weighed and inspected for health and survival at least once a week (checks were more frequent for Apoe -/-Lmna G609G/G609G mice). Diseased animals were examined by a specialized veterinarian blinded to genotype. Animals that met humane end point criteria were euthanized and the deaths recorded. Animals euthanized because of hydrocephalus, malocclusion, intermale aggression, or other reasons unconnected to phenotype were excluded from the analysis (normally at a very early stage of the study).
High-Fat Diet Experiments
For diet-induced atherosclerosis experiments, animals were maintained for 8 weeks on a high-fat diet (HFD) (10.7% total fat, 0.75% cholesterol, S9167-E010, Ssniff) starting at 8 weeks of age. Mice were euthanized at 16 weeks of age after overnight fasting.
Hematology and Serum Biochemical Analysis
Animals were fasted overnight for all blood analyses, which were performed by specialized staff from the Centro Nacional 
Quantification of Atherosclerosis Burden
Mouse aortas were fixed in 4% formaldehyde/phosphatebuffered saline (PBS), cleaned of fatty tissue, and stained with 0.2% Oil Red O (ORO, O0625, Sigma). The thoracic aorta and aortic arch were then cut open longitudinally and pinned out flat, intimal side up, for computer-assisted planimetric analysis. Images were taken with a digital camera (Olympus UC30) mounted on a stereo microscope (Olympus SZX3). The OROstained lesion was quantified as a percentage of total area with SigmaScan Pro 5 (Systat Software Inc) by an observer blinded to genotype.
Histology and Immunofluorescence
For all mice with an Apoe -/background, formaldehyde-fixed aortic arches were cleaned of fatty tissue, incubated in 30% sucrose in PBS overnight at 4°C, and included in Tissue-Tek OCT compound (Sakura) for cryostat sectioning. Mouse hearts were fixed in 4% formaldehyde in PBS, divided into 2 parts (the upper portion containing the aortic root and aortic valve was separated for atheroma plaque analysis), dehydrated to xylene, and embedded in paraffin. Heart sections were prepared at least at 6 levels. The aortic root was sectioned throughout the aortic valve. Serial 4-µm sections were deparaffinized, rehydrated, and stained with hematoxylin and eosin, Masson trichrome, von Kossa, and Perl Prussian blue. For immunofluorescence, antigen retrieval was performed using 10 mmol/L sodium citrate buffer (pH 6). Then samples were blocked and permeabilized for 1 hour at RT in PBS containing 0.3% Triton X-100, 5% bovine serum albumin, and 5% normal goat serum, and incubated overnight at 4°C with anti-CD31 (ab28364, Abcam, 1:100) antibody, and for 2 hours at RT with anti-SMA-Cy3 antibody (C6198, Sigma, 1:200). Next, samples were incubated with anti-rabbit Alexa Fluor-647 secondary antibody (111-607-008, Jackson ImmunoResearch) and Hoechst 33342 for 2 hours at RT, and mounted in Fluoromount-G imaging medium.
ORO, hematoxylin and eosin, Masson trichrome, von Kossa, and Perls Prussian blue-stained sections were scanned with a NanoZoomer-RS scanner (Hamamatsu), and images were exported using NDP.view2. Immunofluorescence images were acquired with a Zeiss LSM700 confocal microscope. Images were analyzed using ImageJ Fiji software by ORIGINAL RESEARCH ARTICLE an observer blinded to genotype. Aortic media and adventitia thickness and medial lipid and VSMC content were analyzed in ≈3 sections of aortic arch per animal, and mean values were used for statistical analysis. Atherosclerotic plaque area, aortic perimeter affected by atherosclerosis, necrotic core size, collagen content, VSMC content, and plaque calcification were quantified in 3 different zones of the aortic root per animal (at the beginning, in the middle, and at the end of the aortic valve), and mean values were used for statistical analysis. Cardiac alterations were assessed near the aortic valve and at least at 6 different levels of the ventricles by a specialized pathologist blinded to genotype.
mRNA Isolation and Reverse Transcription for PCR Detection of Lamin A and Progerin
Liver, kidney, spleen, and heart were homogenized using a TissueLyser (Qiagen), and total RNA was extracted with QIAzol reagent (Qiagen). The RNA pellet was dissolved in RNase-free water, and concentration was measured in a NanoDrop spectrophotometer (Wilmington). RNA (2 µg) was transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
cDNA (200 ng) was amplified by PCR using DNA polymerase (Biotools). Lamin A and progerin mRNAs were detected according to a protocol adapted from Yang et al. 24 PCR products were separated on a 2% agarose gel containing ethidium bromide. Images were taken with a Molecular Imager Gel Doc XR+ System (BioRad) and analyzed with Image Laboratory (BioRad).
LDL Retention in Vivo
Fluorescently labeled human LDL was prepared as described. 25 In brief, human blood from healthy donors was collected in K3EDTA-containing tubes (455036, Vacuette). After centrifugation, plasma was collected, mixed with KBr, and layered on a KBr density gradient column. The column was centrifuged at 256 000g for 18 hours in an Optima L-100 ultracentrifuge (Beckman). The 1.063 g/mL density layer containing LDL was collected, purified on a PD10 column (17085101, GE Healthcare), and conjugated to the fluorochrome Atto 565 N-hydroxysuccinimide ester (72464, Sigma-Aldrich). Atto565-LDL was purified on a PD10 column, and purity was tested at the CNIC Proteomics Unit by liquid chromatographymass spectrometry (High Resolution Orbitrap-Fusion, Thermo Scientific) in an 8% to 27% acetonitrile gradient over 2 hours.
Mice received intravenous injections of Atto565-LDL (15 µg/g body weight). Approximately 20 hours postinjection, animals were anesthetized with pentobarbital (Dolethal, Vetoquinol) and lidocaine (Lidocaine 20 mg/mL, B. Braun Medical S.A.) solution in saline (pentobarbital 1:5, lidocaine 1:50) and perfused with 4% formaldehyde in PBS. Prefixed aortas were extracted, cleaned of fatty tissue, opened longitudinally, and pinned flat on a silicone-covered plate. After overnight fixing in 4% formaldehyde/PBS, aortas were cut into 3 pieces and mounted in glycerol on a microscope slide. Fluorescence images were acquired with a Zeiss LSM780 confocal microscope. Autofluorescence (background) was determined in 2 mice (of each genotype) not injected with Atto565-LDL. ImageJ Fiji software was used to quantify the percentage of the aortic area positive for red fluorescence. Videos were prepared using Imaris software (Bitplane).
Electrocardiography
Mice were anesthetized with 1.5% to 2% isoflurane, and 4 electrocardiography (ECG) electrodes were inserted subcutaneously into the limbs. ECG was performed in the morning using the MP36R system (Biopac Systems). ECG data were analyzed with AcqKnowledge software (Biopac Systems) by specialized staff blinded to genotype.
Statistical Analysis
Experimental data are presented as the mean (error bars indicate SEM) for normally distributed data or median with interquartile range (error bars indicate minimum and maximum) for nonnormally distributed data. Based on all experiments, distribution of a variable (lesion size, nucleus count, etc) was assessed using the Kolmogorov-Smirnov and D'Agostino-Pearson normality tests. If the distribution was normal in most of the experiments, a 2-tailed t test was used. If the distribution of a variable was skewed, the 2-tailed Mann-Whitney test was used. To compare multiple groups, a 1-way ANOVA with the Tukey post hoc test was used for normally distributed data, and a Kruskal-Wallis test with the Dunn post hoc test was used for nonnormally distributed data. A log-rank (Mantel-Cox) test was used to compare Kaplan-Meier survival curves. Differences were considered significant at P<0.05. Statistical analysis was performed with GraphPad Prism 5.
RESULTS

Ubiquitous Progerin Expression in Apoe -/-Mice Accelerates Atherosclerosis
Lmna G609G/G609G knock-in mice ubiquitously expressing progerin recapitulate most clinical manifestations of HGPS, including postnatal growth impairment, lipodystrophy, vascular calcification, and reduced survival (average lifespan: ≈15 weeks). 18, 26 However, we observed no atherosclerosis in aortas of Lmna G609G/G609G mice even when animals were challenged with a HFD for 8 weeks starting at 8 weeks of age ( Figure I in the online-only Data Supplement). This finding is consistent with the observation that mice, unlike humans, are extremely resistant to atherosclerosis development, in part, because of differences in cholesterol and lipoprotein metabolism. 27 To circumvent this limitation, we generated an atherosclerosis-prone mouse model of HGPS by crossing Lmna G609G/+ mice with apolipoprotein E-deficient (Apoe -/-) mice, a widely used atherosclerosis model. 27 As expected, Apoe -/-Lmna G609G/G609G mice showed reduced body weight and a shortened lifespan (median survival, 18.15 weeks) in comparison with Apoe -/-Lmna +/+ littermates with an intact Lmna gene ( Figure 1A through 1C). 
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To study the influence of progerin on atherosclerosis, 8-week-old mice were challenged for 8 weeks with a HFD and euthanized at 16 weeks of age. Pre-HFD serum lipid levels, including total cholesterol, free cholesterol, LDL, and high-density lipoprotein were indistinguishable between experimental groups ( Figure 1D ). However, post-HFD levels were significantly lower in 16-weekold Apoe -/-Lmna G609G/G609G mice than in age-matched Figure 1E ), probably because of reduced food intake associated with the advanced disease progression in progeroid mice. HFD-fed Apoe -/-Lmna G609G/G609G mice nonetheless had a 1.9-fold higher atherosclerosis burden in the aortic arch and a 2.8-fold higher burden in the thoracic aorta ( Figure 1F ) as assessed by ORO staining. Although both groups had focal aortic lesions, the aortic surface of progeroid Apoe -/-Lmna G609G/G609G mice was largely covered with lipid deposits that were not seen in control Apoe -/-Lmna +/+ mice ( Figure 1F , high magnification in bottom images). Histological examination revealed that this abnormality was attributable to excessive lipid accumulation in the aortic tunica media in atheroma-free zones of Apoe -/-Lmna G609G/G609G aorta (Figure 2A ). It is remarkable that Apoe -/-Lmna G609G/G609G mice developed other pathologies present in patients with HGPS, including adventitial thickening ( Figure 2A ) and massive loss of VSMCs within the media ( Figure 2B ). Apoe -/-Lmna G609G/G609G mice also showed significant hematologic alterations, including lower pre-and post-HFD lymphocyte and monocyte counts ( Figure II in the online-only Data Supplement).
VSMC-Specific, But Not Macrophage-Specific, Progerin Expression in Apoe -/-Mice Aggravates Atherosclerosis and Shortens Lifespan
Atherosclerosis is a multifactorial process involving many cell types, including VSMCs and macrophages. 28, 29 Immunohistopathological characterization of atherosclerotic plaques in patients with HGPS suggests that both cell types contribute to progerin-driven atherogenesis. 10 Because Apoe -/-Lmna G609G/G609G mice showed medial VSMC loss and reduced numbers of circulating monocytes (which differentiate to macrophages in ath- ORIGINAL RESEARCH ARTICLE eromata), we generated mice with specific progerin expression in VSMCs or macrophages to study the relative contribution of these cell types to the vascular pathology induced by progerin. We used knock-in Lm-na LCS/LCS mice expressing only lamin C, which produce progerin on crossing with transgenic mice expressing Cre recombinase. 18 Lmna LCS/LCS mice are apparently normal, but are slightly heavier and longer-lived than wild- ORIGINAL RESEARCH ARTICLE type controls. 30 We generated Apoe -/-Lmna LCS/LCS mice and analyzed atherosclerosis in 16-week-old mice that received a HFD during the last 8 weeks. In comparison with control Apoe -/-Lmna +/+ littermates, Apoe -/-Lmna LCS/ LCS mice showed no significant differences in atherosclerosis burden, serum lipid levels, or hematologic parameters ( Figure III Apoe -/-Lmna LCS/LCS LysMCre mice with macrophagespecific progerin expression showed no significant differences in organ size ( Figure VI in the online-only Data Supplement), body weight, or longevity compared with controls ( Figure 3A through 3C) . Although Apoe -/-Lmna LCS/LCS SM22αCre mice with VSMC-specific progerin expression appeared normal early in life ( Figure 3C and Figure VI in the online-only Data Supplement), they stopped gaining weight from ≈20 weeks of age (Figure 3A) , and died prematurely at a median age of 34.3 weeks ( Figure 3B ). Atherosclerosis was studied with the same protocol used for the ubiquitously progerin-expressing Apoe -/-Lmna G609G/G609G mice. The 3 experimental groups showed no intergroup differences in serum lipid levels ( Figure 3D Figure 3F ). Moreover, histological analysis in Apoe -/-Lmna LCS/LCS SM22αCre mice revealed the same marked aortic phenotype observed in the ubiquitous progeroid model, including massive VSMC loss, lipid accumulation in the media, and adventitial thickening (Figure 4 ).
Progerin Expression Accelerates Atherosclerosis in Apoe -/-Mice Fed Normal Chow
To gain insight into the progress of progerin-induced atherogenesis and to assess the role of cho-lesterol in this process, we performed experiments in 8-and 16-week-old mice fed normal chow. Histological examination of aortas from 8-week-old mice revealed no differences between the progeroid models and their controls, with tissue almost free of atherosclerosis and no obvious structural alterations ( Figure VIIIA , VIIIC, and VIIIE in the online-only data supplement). In contrast, the thoracic aortas of 16-week-old Apoe -/-Lmna G609G/G609G and Apoe -/-Lmna LCS/LCS SM22αCre mice presented increased lesion formation than their controls ( Figure VIIIB and VIIID in the online-only Data Supplement). Furthermore, aortas of both mutant models contained regions with VSMC loss ( Figure VIIIE in the online-only Data Supplement). This vascular phenotype was slightly more pronounced in Apoe -/-Lmna LCS/LCS SM22αCre mice than in Apoe -/-Lmna G609G/G609G mice, with lipid retention in the media and adventitial thickening (data not shown), probably because of normal food intake and a consequent cholesterol level similar to that of control mice.
Aortas of Apoe -/-Lmna G609G/G609G and Apoe -/-Lmna LCS/LCS SM22αCre Mice Show Increased LDL Retention
Lipid accumulation in the aortic medial layer is a prominent characteristic of the vascular pathology in both the ubiquitous and the VSMC-specific progeroid mouse models. Because LDL retention in the aortic wall is one of the key processes triggering atherosclerosis initiation and progression, we performed in vivo LDL retention experiments by injecting normal chow-fed 16-week-old mice with human LDL labeled with the fluorochrome Atto565 ( Figure 5A ). Aortic Atto565-LDL content was quantified 20 hours postinjection, at which time exogenous human LDL is cleared from the circulation. 25 In comparison with their respective control littermates, both Apoe -/-Lmna G609G/G609G and Apoe -/-Lmna LCS/LCS SM22αCre mice showed increased aortic LDL retention ( Figure 5B and 5C and Figure IXA and IXB in the online-only Data Supplement). Although Atto565-LDL was localized in the intimal lesions in mice of all genotypes, its excessive retention in the medial layer was exclusive to the ubiquitous and VSMC-specific progeria mouse models ( Figure 5D and 5E, Figure IXC 
Progerin Triggers Plaque Vulnerability
Previous studies have shown that VSMC loss in the tunica media can promote atherosclerotic plaque instability 31 ; we therefore characterized atherosclerotic lesions in the aortic root. Consistent with our results
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in the aorta ( Figures 1F and 3F ), analysis of atheromata in the aortic root revealed a larger lesion area in HFD-fed Apoe -/-Lmna G609G/G609G and Apoe -/-Lmna LCS/ LCS SM22αCre mice than in their respective controls, and this was accompanied by fibrosis and inflammation in the adjacent cardiac tissue ( Figure 6A and 6B) . Moreover, atherosclerosis affected a higher percent-age of the aortic surface in both models ( Figure 6A and 6B). Analysis of Apoe -/-Lmna G609G/G609G and Apoe -/-Lmna LCS/LCS SM22αCre mice revealed the presence in atheromata of erythrocytes, indicating healed plaque fissures ( Figure 6C and 6D, top). We also found hemorrhage in the aortic valve itself ( Figure 6C, bottom) , and evidence of thrombus formation ( Figure 6D , Previous studies reported cardiac electric defects in progeroid Lmna G609G/G609G and Zmpste24-deficient (Zmp-ste24 -/-) mice similar to those found in patients with HGPS. 6, 18, 32 We therefore performed ECG in the ubiqui- 
Apoe -/-Lmna LCS/LCS SM22αCre Mice Die of Atherosclerosis-Related Causes
Despite an almost identical vascular phenotype, ubiquitous and VSMC-specific atherosclerosis-prone progeria models differed in their cardiac phenotype and median survival (18.15 weeks versus 34.3 weeks, respectively). Apoe -/-Lmna LCS/LCS SM22αCre mice, which showed no overt aging phenotype, died suddenly between 26 and 66 weeks of age. It is interesting to note that Lmna LCS/LCS SM22αCre mice with an intact Apoe gene also presented VSMC loss and aortic adventitial thickening, but did not develop atherosclerosis and had a normal lifespan ( Figure XII in the online-only Data Supplement). These findings point to progerin-driven atherosclerosis as the main cause of death in Apoe -/-Lmna LCS/LCS SM22αCre mice. In contrast, Apoe -/-Lmna G609G/G609G mice progressively lost fat tissue, developed bone problems and muscle weakness, and died between 15 and 24 weeks of age, a median survival very similar to that of atherosclerosisfree Lmna G609G/G609G mice. 18 We therefore conclude that the cause of death is likely different in the ubiquitous and VSMC-specific progeria models, at least in the majority of the cases. To analyze cardiovascular alterations, which could reveal the cause of death, we collected aortas and hearts from chow-fed Apoe -/-Lmna G609G/G609G and Apoe -/-Lmna LCS/LCS SM22αCre mice at an age close to their maximum survival (21-23 weeks and 51 weeks, respectively). Atherosclerosis burden in the aortic arch and thoracic aorta was significantly higher in Apoe -/-Lmna G609G/G609G mice than in Apoe -/-Lmna +/+ controls ( Figure 8A ). In comparison with Apoe -/-Lmna LCS/LCS controls, Apoe -/-Lmna LCS/LCS SM22αCre mice showed a higher lesion burden in the thoracic aorta but not in the aortic arch ( Figure 8B ), likely because this athero-prone aortic region is saturated with plaques in 51-week-old (≈1 year) Apoe -/mice. It is important to note that vascular pathology was much more severe in the aorta of 51-week-old Apoe -/-Lmna LCS/LCS SM22αCre mice than in 21-to 23-week-old Apoe -/-Lmna G609G/G609G mice (Figure 8A through 8C) .
Consistent with the findings in the aorta, pathological findings in the aortic root were more severe in Apoe -/-Lmna LCS/LCS SM22αCre mice than in Apoe -/-Lmna G609G/G609G mice (Figures XIII through XVI in the online-only Data Supplement). Plaques in Apoe -/-Lmna G609G/G609G mice were generally immature, frequently exhibiting intraplaque hemorrhages that were absent in age-matched controls ( Figure XIIIA We also performed a histopathologic evaluation of the heart ventricles. Apoe -/-Lmna G609G/G609G hearts were characterized by cardiomyocyte vacuolization, which was absent in Apoe -/-Lmna +/+ , Apoe -/-Lmna LCS/ LCS SM22αCre, and Apoe -/-Lmna LCS/LCS mice ( Figure XVII in the online-only Data Supplement and data not shown). Furthermore, 3 of 9 Apoe -/-Lmna G609G/G609G hearts had coronary atherosclerosis ( Figure 8D and Figure XVI in the online-only Data Supplement) and 2 had a collagen scar in the septum, indicative of a nonfatal infarct ( Figure XVIII in the online-only Data Supplement). Nevertheless, many of the animals analyzed showed no detectable alterations apart from the cardiomyocyte vacuolization ( Figure 8D and 8E) .
Most Apoe -/-Lmna LCS/LCS SM22αCre hearts presented perivascular and interstitial fibrosis, intimal hyperplasia (without cellular infiltrates) and coronary atherosclerosis ( Figure 8D and 8E, Figures XV and XVI in the onlineonly Data Supplement). Some of the animals analyzed also showed evidence of coronary plaque calcification ( Figure 8D ). These pathological alterations in the heart suggest that Apoe -/-Lmna LCS/LCS SM22αCre animals are, like patients with HGPS, susceptible to microinfarcts
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during their lifetime ( Figure 8E ). Collectively, these histopathologic findings in the aorta and heart indicate that Apoe -/-Lmna LCS/LCS SM22αCre animals die of atherosclerosis complications, whereas Apoe -/-Lmna G609G/G609G mice mostly die of atherosclerosis-independent processes.
DISCUSSION
Several mouse models of HGPS have been generated [16] [17] [18] [19] [20] [21] [22] ; however, only a few of these models presented cardiovascular alterations and none showed evidence of atherosclerosis, the pathological process that leads to myocardial infarction-or stroke-related death in most children with HGPS. Based on these models, vari-ous molecular mechanisms have been proposed to explain how progerin drives HGPS. Treatments targeting candidate pathways have significantly ameliorated disease progression and extended lifespan in mice; however, these treatments have only had modest therapeutic effects in patients with HGPS. [33] [34] [35] One possible explanation is that progeric mice, unlike humans, die of atherosclerosis-independent causes. It is important to note that mice are particularly resistant to atherosclerotic plaque formation, in part, because of the murine blood lipid profile, with high atheroprotective highdensity lipoprotein and low atherogenic LDL. 36 Thus, to study atherosclerosis in mouse models, it is usually necessary to introduce a genetic mutation (such as in- ORIGINAL RESEARCH ARTICLE activation of the Apoe or Ldlr genes), to alter their lipid metabolism and make them more prone to developing atherosclerosis. 37, 38 In this study, we generated Apoe -/-Lmna G609G/G609G mice, the first mouse model of progerin-induced atherosclerosis acceleration. In addition to enhanced ath- ORIGINAL RESEARCH ARTICLE eroma plaque formation, these animals exhibit massive loss of medial VSMCs and prominent adventitial thickening and fibrosis, important hallmarks of vascular disease in HGPS. [8] [9] [10] These features were previously observed in knock-in Lmna G609G/G609G and transgenic G608G BAC mouse models [17] [18] [19] ; however, in earlier models, these features did not manifest as early or as severely as described here and were not accompanied by atherosclerosis development. The Apoe -/-Lmna G609G/ G609G model is also the first to show lipid accumulation in atheroma-free zones of the aortic media, which may contribute to enhanced plaque formation. Furthermore, our studies with Apoe -/-Lmna LCS/LCS SM22αCre mice (VSMC-specific progerin expression) and Apoe -/-Lmna LCS/LCS LysMCre mice (macrophage-specific progerin expression) provide the first direct evidence that restricting progerin expression to VSMCs, but not macrophages, is sufficient to accelerate atherosclerosis and reduce lifespan. Although limiting progerin expression to macrophages does not increase atherosclerosis burden or reduce survival, it remains to be determined whether it affects plaque composition. Further studies are also required to ascertain why progerin-expressing Apoe -/mice have increased lipid retention in the media (eg, increased vascular permeability, changes in the extracellular matrix amount and composition). Our findings in both the ubiquitous and the VSMCspecific progerin mouse models indicate that VSMCs are particularly sensitive to progerin accumulation. Progerin-induced VSMC death results in increased LDL retention in the media, adventitial thickening, and accelerated atherosclerosis. Similarly to Clarke et al, 31 we found that VSMC death triggers features of plaque vulnerability, which may lead to myocardial infarction and premature death. Our results demonstrate the importance of VSMCs in progerin-driven atherosclerosis and identify this cell type as a key target for future treatments.
It is remarkable that we observed that Apoe -/-Lmna G609G/G609G mice have a similar average lifespan to nonatherosclerotic Lmna G609G/G609G mice, suggesting that mice with ubiquitous progerin expression die of atherosclerosis-independent causes, unlike human patients with HGPS. In contrast, Apoe -/-Lmna LCS/LCS SM22αCre mice appear to die of atherosclerosis-related problems, because Lmna LCS/LCS SM22αCre mice, with VSMC-specific progerin expression but an intact Apoe gene, did not develop atherosclerosis and had a normal lifespan. This hypothesis is supported by histopathologic findings in mice at ages close to their maximum survival, which reveal much more severe aortic and coronary atherosclerosis in Apoe -/-Lmna LCS/LCS SM22αCre mice than in Apoe -/-Lmna G609G/G609G mice. It may be that plaque disruption leading to infarction and death occurs in Apoe -/-Lmna G609G/ G609G mice, but only in animals surviving to near 26 weeks of age. This is well beyond the median survival in this model (18.15 weeks), but is the age at which Apoe -/-Lm-na LCS/LCS SM22αCre mice begin to die. Although Apoe -/-Lmna G609G/G609G mice may die of heart failure, the cause would likely be related to complications such as arrhythmia, rather than atherosclerosis, as supported by ECG studies in this model. Similarly, we previously reported that Lmna G609G/G609G mice have a prolonged QRS-complex duration, indicating defective cardiac conduction. 18 Likewise, our studies in Zmpste24-null mice, another model of premature aging caused by defective prelamin A processing, revealed PQ and QRS prolongation and T-wave flattening, which may increase the risk of lethal arrhythmias in the setting of progeria. 32 This result is also consistent with the observation that patients with HGPS show repolarization abnormalities resulting in an increased risk of arrhythmias and premature death. 32 In summary, atherosclerosis-prone Apoe -/-Lmna G609G/ G609G mice faithfully recapitulate most aspects of human HGPS, including growth retardation, shortened lifespan, and early CVD onset, and is therefore a valuable tool for investigation of the general mechanisms underlying HGPS. We have also demonstrated that VSMC-restricted progerin expression in Apoe -/-Lmna LCS/LCS SM22αCre mice is sufficient to induce the vascular features of progeria independently of growth retardation and other disease symptoms, thus providing a unique preclinical model for the study of atherosclerosis and atherosclerosis-associated premature death in isolation from other signs of premature aging. Another advantage of these animals is the lack of overt growth defects, which might permit the testing of diagnostic techniques and interventional strategies that are unavailable in the undersized Apoe -/-Lmna G609G/G609G model.
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